Entrada Therapeutics Inc (TRDA) AI Stock Analysis

• Market Cap: $235.45M
• Dividend Yield: N/A
• Average Volume (3M): 326.39K
• Price to Earnings (P/E): 7.4
• Beta (1Y): 1.59
• Revenue Growth: -66.80%
• EPS Growth: -157.68%
• Country: US
• Employees: 183
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.04
• Shares Outstanding: 38,037,080
• 10 Day Avg. Volume: 179,944
• 30 Day Avg. Volume: 326,388
• PEG Ratio: -0.01
• Price to Book (P/B): 1.50
• Price to Sales (P/S): 3.06
• P/FCF Ratio: -14.43
• Enterprise Value/Market Cap: -0.09
• Enterprise Value/Revenue: -0.27
• Enterprise Value/Gross Profit: -0.28
• Enterprise Value/Ebitda: 0.23
• 1Y Price Target: $18.50
• Price Target Upside: 198.87% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 49 Neutral
• Price Target: $6.00 ▼(-3.07% Downside)

The overall stock score of 49 reflects significant financial challenges, particularly in revenue generation and profitability, which are the most impactful factors. Technical analysis shows moderate bullish momentum, but valuation concerns due to negative profitability weigh heavily on the score. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Proprietary Technology

Entrada's TET platform provides a competitive edge by enabling effective delivery of therapeutic agents into cells, potentially leading to successful treatment of genetic and rare disorders.

Partnerships and Collaborations

Strategic partnerships enhance Entrada's research capabilities and revenue potential through milestone payments and royalties, supporting long-term growth.

Moderate Leverage

Moderate leverage suggests Entrada has a manageable debt load, providing financial flexibility to invest in R&D and strategic initiatives.

Negative Factors

Revenue Decline

Significant revenue decline indicates challenges in product commercialization and market penetration, affecting long-term financial stability.

Negative Cash Flow

Negative cash flow highlights difficulties in sustaining operations and funding R&D, potentially hindering future growth and innovation.

Profitability Challenges

Ongoing profitability challenges suggest inefficiencies in cost management and revenue generation, impacting long-term viability and shareholder returns.

Entrada Therapeutics Inc Business Overview & Revenue Model

Company Description

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Entrada Therapeutics generates revenue through a combination of product development partnerships, grants, and potential future product sales. The company collaborates with pharmaceutical firms and research organizations to develop its therapies, often receiving milestone payments and royalties from these partnerships. Additionally, Entrada may receive funding from government and non-profit organizations aimed at supporting research in rare and genetic diseases. As the company advances its drug candidates through clinical trials, it may also attract further investments and partnerships, enhancing its revenue potential.

Entrada Therapeutics Inc Financial Statement Overview

Summary

Entrada Therapeutics Inc. faces significant financial challenges, particularly in revenue generation and profitability. Despite a strong gross profit margin, the company struggles with negative net profit and EBIT margins, moderate leverage, and cash flow issues.

Income Statement

Entrada Therapeutics Inc. has experienced significant volatility in its revenue and profitability. The TTM data shows a sharp decline in revenue by 53.85%, with negative net and EBIT margins indicating ongoing losses. Despite a strong gross profit margin, the company struggles with profitability, as evidenced by negative net profit and EBIT margins.

Balance Sheet

The balance sheet reflects moderate leverage with a debt-to-equity ratio of 0.14, indicating manageable debt levels. However, the company has a negative return on equity, suggesting inefficiencies in generating returns for shareholders. The equity ratio is stable, showing a solid equity base relative to total assets.

Cash Flow

Cash flow analysis reveals challenges in cash generation, with negative operating cash flow and free cash flow. The free cash flow growth rate is positive, but the operating cash flow to net income ratio is negative, indicating cash flow issues despite some improvement in free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	79.48M	210.78M	129.01M	0.00	0.00	0.00
Gross Profit	76.48M	210.78M	29.13M	-1.90M	-1.12M	-326.00K
EBITDA	-94.23M	47.01M	-321.00K	-95.35M	-50.01M	-26.34M
Net Income	-73.35M	65.63M	-6.68M	-87.46M	-50.07M	-26.38M
Balance Sheet
Total Assets	448.78M	526.32M	469.19M	252.06M	305.83M	43.53M
Cash, Cash Equivalents and Short-Term Investments	354.01M	420.00M	351.97M	45.16M	291.06M	39.05M
Total Debt	54.74M	59.21M	68.23M	25.94M	0.00	0.00
Total Liabilities	69.28M	97.64M	226.83M	39.50M	7.12M	85.02M
Stockholders Equity	379.50M	428.68M	242.36M	212.55M	298.72M	-41.49M
Cash Flow
Free Cash Flow	-126.56M	-44.72M	134.19M	-96.67M	-55.44M	-27.89M
Operating Cash Flow	-123.87M	-41.56M	139.80M	-93.79M	-50.86M	-25.57M
Investing Cash Flow	9.02M	-27.80M	-138.40M	-148.65M	-4.58M	-2.32M
Financing Cash Flow	2.08M	102.96M	21.04M	479.00K	307.46M	50.09M

Entrada Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.19
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRDA, the sentiment is Positive. The current price of 6.19 is above the 20-day moving average (MA) of 5.81, above the 50-day MA of 5.56, and below the 200-day MA of 8.70, indicating a neutral trend. The MACD of 0.18 indicates Negative momentum. The RSI at 56.66 is Neutral, neither overbought nor oversold. The STOCH value of 30.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TRDA.

Entrada Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GNFT	53 Neutral	$213.02M	109.67	-51.06%	―	-44.94%	-274.42%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TRDA	49 Neutral	$235.45M	7.36	-18.12%	―	-66.80%	-157.68%
CCCC	47 Neutral	$158.00M	―	-52.99%	―	16.55%	16.73%
SGMT	44 Neutral	$236.23M	―	-37.89%	―	-100.00%	-62.44%
VTYX	41 Neutral	$282.38M	―	-48.56%	―	―	39.76%
BDTX	33 Underperform	$236.28M	17.53	11.85%	―	―	―

Entrada Therapeutics Inc Corporate Events

Entrada Therapeutics Holds Virtual Annual Stockholders Meeting

On June 11, 2025, Entrada Therapeutics, Inc. held its Annual Meeting of Stockholders virtually, where a quorum was established with 30,259,526 shares represented. During the meeting, stockholders elected three Class I directors to the Board and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Entrada Therapeutics Appoints New Board Member

On May 30, 2025, Entrada Therapeutics expanded its Board of Directors from six to seven members, appointing Maha Radhakrishnan, M.D., as a Class III director and a member of the Audit Committee, effective June 1, 2025. Dr. Radhakrishnan brings extensive experience in global drug development, which is expected to support Entrada’s clinical momentum, particularly in advancing its Duchenne muscular dystrophy programs. Her appointment is seen as a strategic move to enhance the company’s capability in delivering innovative therapies for serious illnesses.